<DOC>
	<DOCNO>NCT02447679</DOCNO>
	<brief_summary>This single-centered phase II clinical study obtain preliminary information 1-year recurrence-free survival rate , recurrence-free survival safety profile thalidomide combination tegafur-uracil hepatocellular carcinoma hepatectomy explore biomarkers ( VEGF/bFGF ) thalidomide response .</brief_summary>
	<brief_title>Oral Thalidomide Tegafur-uracil Decrease Hepatocellular Carcinoma Recurrence</brief_title>
	<detailed_description>After liver resection remove hepatocellular carcinioma completely , patient high risk tumor recurrence enrol study . The high risk tumor recurrence depend tumor characteristic . The risk factor tumor characteristic include tumor size &gt; 5 cm diameter , abscence encapsulation , vascular invasion presence daughter nodule . The patient high risk tumor recurrence 1 3 risk factor . When patient enrol study , oral thalidomide combination tegafur-uracil applied prevent tumor recurrence . The patient fillowed uo erevy 3 mnoths .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Drug-Related Side Effects Adverse Reactions</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>1. stage IIII（TNM : T1T3） hepatocellular carcinoma 2. previously receive curative surgery 3. presence least one three follow risk factor , i.Tumor size ≧ 5 cm ii.presence microscopic macrovascular venous invasion iii.presence satellite nodules/addition nodule iv.no capsular formation v.multiple tumor d.performance status ECOG 0 , 1 e.age 20 75 year f.no residual recurrent tumor detect computed tomography ( CT ) echo within 36 week surgery g.written inform consent participate trial 1. malignancy exception curative treat nonmelanoma skin cancer cervical carcinoma situ prior entry study 2. previously receive chemotherapy 3. less 2 week since previous radiotherapy/surgery 4. white blood cell ( WBC ) less 3,000/mm3 absolute neutrophil count ( ANC ) less 1,500/mm3 , platelet less 100,000/mm3 5. serum bilirubin great 1.5 time upper limit normal range ( ULN ) 6. alanine aminotransferase ( ALT ) aspartate transaminase ( AST ) great 5 time ULN 7. alkaline phosphatase great 5 time ULN 8. presence serious concomitant illness might aggravate study medication : uncontrolled infection ( active serious infection control antibiotic ) 9. hypersensitivity thalidomide compound pregnant breast feed woman , woman childbearing potential unless use two reliable appropriate contraceptive method</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>